Disclosed herein is a pharmaceutical tablet for oral administration comprising ulipristal acetate (17alpha-Acetoxy-11beta-[4-N,N-dimethylamino-phenyl]-19-norpregna-4,9-diene-3,20-dione) in an amount of 3 to 18 wt%, together with the following excipients: a diluent in an amount of 60 to 95 wt%, wherein the diluent may be selected from a monosaccharide, a disaccharide, a derivative polyol of a monosaccharide and hydrates thereof； a binding agent in an amount of 0 to 10 wt%, wherein the binding agent may be selected from hydroxypropyl methyl cellulose and povidone； croscarmellose sodium in an amount of 1 to 10 wt%, and magnesium stearate in an amount of 0 to 5 wt%, wt% designating an amount by weight, as a percentage of the total weight of the composition.
